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Objectives: To evaluate the efﬁcacy of a healthcare education program for patients with hypertension.
Methods: A multicenter, prospective, cluster-randomized trial was conducted. Randomization was by
primary care center; 18 of 36 urban primary care centers in Barcelona and its metropolitan area were
randomized to the intervention group (IG) and 18 to the control group (CG). The study sample consisted
of patients with hypertension (n=996; 515 in the IG and 481 in the CG) receiving outpatient treatment
with antihypertensive drugs. The intervention consisted of personalized information by a trained nurse
and written leaﬂets. Questionnaires on knowledge and awareness of hypertension and its medication,
treatment adherence, healthy lifestyle habits, systolic and diastolic blood pressure, and body mass index
were assessed at each visit, with a 12-month follow-up. An intention-to-treat analysis was applied.
Results: Knowledge of hypertension increased by 27.8% in the IG and by 18.5% in the CG, while that
of medication increased by 10.1% in the IG and 5.5% in the CG. Treatment adherence measured by the
Morisky-Green test increased by 9.6% (95% CI: 5.5–13.6) in the IG and 8.8% (95% CI: 4.9-12.6) in the CG.
There were no differences in adherence on the other tests used. No differences were observed between
the IG and CG in clinical variables such as blood pressure or BMI at the end of the trial.
Conclusions: The educational intervention had no signiﬁcant impact on patients’ adherence to the med-
ication.
© 2010 SESPAS. Published by Elsevier España, S.L. All rights reserved.
Conocimiento y adherencia a la terapia antihipertensiva en atención primaria:
resultados de un ensayo clínico
alabras clave:
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ducación sanitaria
r e s u m e n
Objetivos: Evaluar la eﬁcacia de un programa de educación sanitaria en pacientes con hipertensión.
Métodos: Se disen˜ó un estudio multicéntrico prospectivo y aleatorizado de conglomerados. La unidad de
aleatorización fueron los centros de atención primaria (CAP) situados en Barcelona y su área metropoli-
tana, con 18 CAPs urbanos asignados al grupo intervención (GI) y 18 al grupo control (GC). La muestra
de pacientes hipertensos que recibían tratamiento con antihipertensivos ambulatoriamente fue de 996
(GC=481 y GI =515). La intervención consistió en información personalizada mediante enfermera entre-
nada y material educativo escrito. Se midió en cada visita la presión arterial, el índice de masa corporal, el
conocimiento de la enfermedad y de la medicación, la adherencia al tratamiento y los hábitos saludables;
el seguimiento fue de 12 meses. Para el análisis de los datos se aplicó el criterio de intención del tratar.
Resultados: El conocimiento de la enfermedad aumentó un 27,8% en el GI y un 18,5% en el GC, así como
el de la medicación un 10,1% en el GI y un 5,5% en el GC. La adherencia al tratamiento mediante la prueba
de Morisky-Green aumentó un 9,6% en el GI y un 8,8% en el GC. No se observaron diferencias entre GI y
GC en las otras medidas de adherencia, ni en las variables clínicas relativas a la presión arterial o el índice
de masa corporal al ﬁnal del ensayo.
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Introduction
Control of hypertension is associated with long term health
outcomes.1,2 Adherence to pharmacological and non pharmaco-
logical therapy is essential in order to achieve such control.3–5
Adherence can be deﬁned as the extent to which a person’s
behavior correspondswith agreed recommendations from a health
care provider.6 Problems with follow-up of therapeutic recom-
ts reserved.
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endations are common in almost all pathologies7 and highly
mpacts the effectiveness of the treatment.8 The main factors
elated to adherence are the complexity of the therapeutic reg-
men and the adaptability of the recommendations to the usual
abits of the patient. Also, the patient’s knowledge about the
athology, previous experience with the health-care system,
dherence to other previous recommendations, the doctor-patient
elationship, patient’s perception of health, and the beneﬁts
f the proposed recommendations are factors associated with
dherence.6,9,10
Several interventions are proposed to improve adherence.
ritical reviews have highlighted signiﬁcant methodological
roblems,11-16 but the overall conclusion is that no single inter-
ention is, per se, better than any other. A further conclusion
s that combined cognitive and behavioural strategies are the
ost effective ones, and the evidence indicates that these aspects
eed to be incorporated into the design of strategies to improve
dherence in the treatment of hypertension.12,13 Haynes et al.13
uggested that the interventions used need to be easy to apply in
he health-care practice, and maintained over extended periods of
ime.
In the case of the hypertension, a condition that can exist for
ears without clinical symptoms, the problem of non-adherence
nd how to cope with it has long been recognized, and different
ecommendations have been introduced.3,15 In Spain,17,18 the per-
entage non-adherence to hypertension treatments is around 50%,
level similar to that of other countries and/or pathologies. Hyper-
ension is a risk-factor for cardiovascular disease and is detected,
valuated, and treated mostly in the primary health-care setting.
n Spain, the long-term control and follow-up of the hypertensive
atient on an established treatment program is usually carried-
ut by clinic nurses under the direction and close supervision of
he attending physician.19 This is also the case for other chronic
athologies such as diabetes or chronic bronchitis, as well as giving
dvice about diets and healthy lifestyle habits.20
The hypertensive patient with a long disease history can bene-
t from interventions that focus on improving adherence to the
rug treatment in the primary health care setting as well as
on-pharmacologic measures to improve control of hypertension.
urses take care of the long term followupof hypertensive patients
n the primary health care setting.
We assessed the impact of information provided to patients
n a personalized way by the clinic nurse with the objective of
mproving the patient’s knowledge of the disease and adherence to
he medication prescribed as well as the incorporation of healthy
ifestyle habits. Also, we assessed the potential impact on systolic
nd diastolic blood pressure and body mass index (BMI).
aterials and Methods
tudy design
The study was designed as multi-centre, prospective, cluster-
andomised, controlled clinical trial, using the primary healthcare
entre as a randomization unit. Patients under anti-hypertensive
rug therapy receiving the intervention (Intervention Group; IG)
ere compared with a control group (CG) receiving the usual clin-
cal care.
ettingThe trial was conducted in Primary Health Care Centres (PHCC)
ocated in Barcelona, Spain, and its metropolitan area. There were
6 centres involved (18 in the CG and 18 in the IG). One hundred
en nurses participated in the study, with 54 participating in the IG.anit. 2011;25(1):62–67 63
Study population
Eligible patients were consecutively selected by their nurse,
who informed them about the study objectives, and recruited all
patients who agreed to participate. Patients were included if they
had hypertension, were aged between 18 and 80 years, visiting the
clinic for long-term follow-up and control of hypertension using
anti-hypertensive drug therapy, and had attended the clinic for a
minimum period of 6 months.
Individuals who had serious psychiatric, physical, or sensory
alterations were excluded. The study protocol was approved by
the Ethics and Research Committee of the Institut d’Investigació en
Atenció Primària Jordi Gol i Gurina (Institute of Research in Primary
Health Care in Catalonia).
The sample size requirement was estimated assuming a
percentage of self-declared non-adherence to the hypertensive
treatment. Given that previous studies observed a high degree of
variability in this percentage (range, 16–60%), the sample was cal-
culated using a non-compliance value of 40%. This implied a sample
size of 487 individuals in each group were needed to detect a mini-
mum of 10% reduction (at the end of the instructions/intervention)
in the percentage non-compliers between the two groups (an alpha
error of 5% and a beta error of 20%, with a loss to follow-up estima-
tion of 20%).
Patients allocated to the control group received theusual clinical
care without any standardized intervention, which usually implies
a high inter-individual variability.
Intervention design
Intervention was developed during the 3 phases described
below.
1) Nurse training: the IG nurses took part in a 10-hour workshop
focused on the anti-hypertension medications with an emphasis
on adverse effects, pharmacological interactions, and patient
centring with a special focus on comorbidity issues and other
clinical variables. Between 6 and 10 nurses participated in each
workshop. The programme consisted of two 4-hour sessions
and one 2-hour session. To assure standardisation of the group
sessions, 4 qualiﬁed pharmacists with extensive expertise in
training activities, as well as in hypertension therapies and
patient education, conducted the sessions. Speciﬁcally designed
educational material was provided to all participating nurses.
2) Developing guidelines to standardize the information given to
patients: guidelines to standardize the information that nurses
should provide to patients were developed by the research team.
These contained key information about the disease, healthy
lifestyle habits, and messages targeted to each group of antihy-
pertensive drugs used (mechanism of action, dosage, what to do
if a pill is missed, adverse effects, and other recommendations).
Also, the guidelines were designed as leaﬂets that allowed the
development of a personalised therapeutic plan; general health
messages aimed at promoting the good utilization of drugs.
3) Direct intervention with the patient: four visits were planned
by the nurse to carry out the intervention, using the stan-
dardised guidelines developed for the intervention. Each visit
lasted for an average of 15minutes. The information provided
to the patient was personalized according to the needs of the
patient.
Furthermore, schedule sheets with the treatment plan were
provided, which contained information on the drugs prescribed,
the dosage and schedule, and basic advice on how to maxi-
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ize the treatment schedules. The purpose of these sheets was
o reinforce the nurse’s verbal instructions and advice to the
atient.
easurement and data collection
All the information was obtained from a questionnaire
dministered at the start and at the 3-, 6- and 12-month
ollow-up visits. The interview was conducted by the nurse
sing forms speciﬁcally designed for the purpose. Clinical
ata were extracted from the clinical record by the nurse.
he variables recorded at the initial visit (V0) and at the
nd of the 12-month follow-up (V4) included the following:
ociodemographic (gender, age, education level); knowledge area
knowledge of hypertension and the anti-hypertension med-
cations, recommendations regarding healthy lifestyle habits);
atient adherence area (self-declared adherence to medication
ntake, pill count, and adherence to lifestyle recommendations);
linical (years since diagnosis of hypertension, systolic and dias-
olic blood pressure control of hypertension, BMI, number of
nti-hypertensive drugs, other drugs taken, total number of
rugs).
Blood Pressure (BP) was measured using a regularly-calibrated
ercury sphygmomanometer. The mean of 2 determinations was
oted in the control arm (highest BP) with at least 2minutes
eparating the measurements. A value of <140/90 mmHg was con-
idered indicative of good blood pressure control.
The BMI was calculated as the weight (in kg) divided by the
eight (in m2).
The drug therapies prescribed for each participantwere codiﬁed
ccording to the ATC.21
The patient’s knowledge or awareness of hypertension was
valuated using the Batalla test.22 Good knowledge of the dis-
ase required correct responses to the 4 questions on this topic
n the questionnaire. Similarly, the patient’s knowledge of anti-
ypertensive drugs and recommendations for healthy lifestyle
abits were obtained from the speciﬁc questions on these topics
n the questionnaire.
Self-reported adherence to the medication was measured using
he Haynes-Sackett and Morisky-Green tests, which were previ-
usly translated and validated,23,24 together with the patient’s
ecall of the medications taken over the previous 3 months.
he level of adherence on the Haynes-Sackett test was consid-
red good if the patient answered «I had no difﬁculties with
edication intake»; for the Morisky-Green test, adherence was
ssessed as the combined positive agreements to the follow-
ng statements: «I do not forget to take a pill», «I take it at
he scheduled time», and «I do not miss any pill when I am
n good health”, and the declaration of having taken the pills
ver the previous 3 months «every day or most days». Adher-
nce to medication was also evaluated based on pill counts, in
hich good compliance was considered to have occurred if the
edication taken was between 80% and 110% of the pills pre-
cribed.
tatistical analysis
The analyses were performed under the intention-to-treat cri-
eria. To address potential biases caused by incomplete follow-up,
e analyzedpatientswith incomplete data using thebaseline value
arried forward to replace missing values.Differences between groups andwithin visit datawere analyzed
sing statistical tests for independent data. Changes within the
ame groups between the initial and ﬁnal clinic visits were eval-
ated using tests for related data. Cluster randomization was taken
nto account in the analysis using either a robust method for theanit. 2011;25(1):62–67
calculation of standard errors. This analysis was carried out using
the software R. The remaining analyses were carried out using
the SPSS statistical package for Windows, version 13 (SPSS Inc.,
Chicago, IL).
Results
The sample population included 515 subjects in the IG and 481
in the CG. During the follow-up, 79 patients in the IG (15.3%) and 49
(10.2%) in the CG exited the study (Fig. 1). No signiﬁcant differences
were observed between those who completed the study and those
who did not (data not shown).
At the initial outpatient visit, the groups were comparable
except that the BMI was signiﬁcantly higher in the IG than the
CG (Table 1). The mean age was 63 years, most participants were
female, and two thirds of the participants had no formal education.
About half of the participants had poor control of their hyperten-
sion, and theBMI inbothgroups indicatedconsiderableobesity. The
mean time since diagnosis of hypertensionwas 10 years. According
to the Batalla test, one of every three patients was aware of hyper-
tension as a disease. The majority of the participants knew about
the anti-hypertension medications they had been prescribed and
rememberedmore than two recommendations for healthy lifestyle
habits.
In relation to the self-declared compliance, there was a diver-
gence of ﬁndings depending on the test employed; 4% of patients
declared difﬁculties with compliance on the Haynes-Sackett test,
whereas non-compliance was 25% with the Morisky-Green test,
and 12% with pill counting.
Table 2 summarises the changes observed within each group,
presenting the intra-group differences (ﬁrst and second columns
in Table 2) comparing the data at the beginning and end of the
study for each group separately, and inter-group differences (third
column in Table 2) between the IG and the CG after 12 months of
follow-up, including the 95%conﬁdence interval (CI) of the differ-
ence. In both groups, all the variables in the awareness category
improved signiﬁcantly. The magnitude of the increase in knowl-
edge of hypertension was much greater in the IG, according to
the Batalla test. Indirect measures of adherence did not show
improvement following the intervention, with the exception of the
Morisky-Green test. At the end of the study, there were no statisti-
cally signiﬁcant differences between the IG and CG groups, except
in the Haynes-Sackett measure of adherence.
Discussion
The educational intervention carried out in this study was
directed towards improving knowledge and adherence in individ-
uals regularly attending an educational program during outpatient
visits scheduled by the primary care nurse. The aim was to achieve
better control of hypertension. The study population had a long
history of hypertension and a high BMI. The strengths of the study
were the larger than usual study sample13 and the 12-month inter-
vention period, which was also longer than those reported in the
literature. However, the outcomes of this study were negative. This
could be partially explained by the study population characteristics
and the intervention itself.
Regarding the study population, although adherence to pre-
scribed medication and the non-pharmacological methods is a key
element in the control of hypertension,3,4,25,26 the long-term evo-
lution of the condition in our study population implied a high risk
of non-adherence, since there is evidence that adherence decreases
with time elapsed since diagnosis.9 Nevertheless, the level of non-
compliance declared by the patients was much lower than that
observed in other samples of hypertensive patients in Spain. A
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PHCC
Allocation
Assigment
Patient consults nurse for hypertension
follow-up and evaluated.
Fulfilled inclusion criteria 
N = 1023
PHCCa accepts patient to participate
Intervention Group
PHCC = 18; participants n = 515
Control Group
PHCC = 18; participants n = 481
Lost to follow up (n= 49)  Lost to follow up (n = 79) 
* Patient changed residence (n = 44)
* Patient admitted to hospital (n = 12)
* Voluntary with drawal of the patient (n = 23)   
* Patient changed residence (n = 24)
* Patient admitted to hospital (n = 5)
* Voluntary with drawal of the patient (n = 20)   
Patients who completed the trial (n = 436) Patients who completed the trial (n = 432)
Randomized participants (n = 996)
Lost to follow-up
Change of PHCC for two investigators; n = 15
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Figure 1.
eta-analysis by Puigventós et al.17 of the studies carried out in
pain and using the Morisky-Green test for comparison indicated
percentage of self-declared non-compliers of 55%, whereas this
as 25% in our study. This difference could be partially explained
ecause our study sample included individuals who were regular
ttendees of the follow-up visits scheduled by the primary health-
are team, and who had a long history of hypertension, and the
uestionnaire was administered at their own health-care centre.
n fact, the prevalence of non-adherence in hypertension has been
onsidered highly dependent on the study population.15
Baseline data indicated that a control of hypertension of 40%
as lower than that observed in other studies conducted in Spain
s part of the MONICA project,27 indicating that there was room
or improvement. However, after the intervention, no improve-
ent in the control of the hypertension was observed. Studiesow chart.
performed in Spain that impacted compliance and control of hyper-
tension were those focusing on recently-diagnosed patients with
high blood pressure and, as such, were more likely to be predis-
posed towards greater adherence. Our results are consistent with
the small effects of interventions aimed at improving adherence,
with HTA observed in two meta-analysis,28,29 a recent review15, or
in chronic conditions in general.30 However, the results obtained
in this study, especially the sub-optimal control of blood pressure
and the elevated BMI, underline the need for speciﬁc interventions
with special emphasis on diet and exercise, which are not easy to
carry out effectively in practice.31The intervention was planned within the context of standard
clinical practice and the criteria suggested by Haynes et al.13 This
study was carried out with the aim of ease of application in the
primary care setting, >80% follow-up of patients, andwith clinically
66 E. Amado Guirado et al / Gac Sanit. 2011;25(1):62–67
Table 1
Characteristics of the control and intervention groups at the ﬁrst visit to the healthcare clinic
Variables Intervention N=515 Control N=481 P value
Socio-demographic variables
Females (%) 67.7 64.2 .241
Age; mean (SD) 63.3 (8.1) 63.4 (8.9) .912
Education
No formal education (%) 67.2 61.7 .150
Primary school (%) 25.8 28.9
Secondary school or university (%) 7.0 9.4
Clinical data and treatment variables
Years since diagnosis; mean (SD) 10.9 (8.3) 9.9 (6.9) .074
Systolic blood pressure (mmHg); mean (SD) 140.9 (16.2) 139.3 (15.0) .112
Diastolic blood pressure (mmHg); mean (SD) 82.5 (8.9) 82.2 (8.8) .704
Patients with controlled hypertension (%) 39.8 45.3 .351
Body mass index (kg/m2); mean (SD) 30.2 (4.8) 29.5 (4.3) .022
Number anti-hypertensive drugs; mean (SD) 1.42 (0.63) 1.36 (0.6) .059
Persons taking other drugs (%) 66.6 63.6 .348
Total number of drugs; mean (SD) 2.9 (1.7) 2.6 (1.5) .059
Knowledge
Batalla test: knowledge of the hypertension (%) 31.5 28.7 .342
Knowledge of hypertensive drugs (%) 71.3 68.5 .110
Lifestyle recommendations; mean (SD) 2.8 (1.4) 2.7 (1.4) .194
Adherence
Haynes-Sackett test; adherence (%) 95.5 96.9 .318
Morisky–Green test; adherence (%) 75.1 75.7 .877
96.7
87.8
86.8
S
r
t
t
c
b
s
e
c
i
t
T
D
VSelf-reported adherence over 3 months; adherence (%)
Pill count; adherence (%)
Life-style recommendations followed; adherence (%)
D: standard deviation.
elevant outcomes in a large sample population that was main-
ained over a relatively long period. Our intervention was directed
owards inducing a higher level of knowledge and behavioural
hanges in the patient, mostly through an intervention delivered
y a trained nurse on the primary care team,32 which has been
hown to be feasible but ineffective in HTA patients with long term
volution of the condition.
Several limitations of this study should be considered. Firstly,
ontamination of the CG. The majority of the outcomes improved
n both groups over the 12-month follow-up. The randomization
o the intervention according to the Primary Health-care Centre
able 2
ifferences within groups and between groups with respect to knowledge, compliance, a
Variable Intervention
V4 – V0 n=5
Mean chang
Clinical data and drug treatment
Systolic blood pressure (mmHg), differences in means –0.67 (–2.63
Diastolic blood pressure (mmHg), differences in means –1.43 (–2.67
Hypertension controlled, differences in means 1.4 (–2.6
Body mass index (kg/m2), differences in means 0.09 (–0.01
Number of antihypertensive drugs, differences in means 0.02 (–0.01
Knowledge
Batalla test: knowledge of the disease expressed as
percentage of change in knowledge
27.8 (18.4
Knowledge of anti-hypertensive drugs expressed as
percentage of change in knowledge
10.1 (6.3 to
Life-style recommendations expressed as a differences
between groups in means
0.23 (0.04
Adherence
Haynes-Sackett: expressed as percentage of change in
adherence
–1.2 (–3.0
Morisky-Green test: expressed as percentage of change in
adherence
9.6 (5.5 to
Previous 3 month adherence; reported every day/most days
expressed as percentage of change in adherence
1.6 (–0.1
Pill count: expressed as percentage of change in adherence 2.5 (–1.2
Life-style recommendations; declared always/almost always
expressed as percentage of change in adherence to
recommendations
4.6 (1.7 to
0: initial visit; V4: visit at 12 months.97.5 .492
88.9 .604
89.5 .261
decreases the possibility of contamination between the groups;
also, cluster randomisation was taken into account in the analysis.
However, the administrationof the follow-upquestionnaire at each
clinic visit, the protocol of scheduled clinic visits in both groups,
and the effect of participating in a clinical trial could explain the
improvements observed in the CG.33 Secondly, the nurse-led inter-
vention had the advantage of proximity to the patient, but also
the long-term clinical relationship these patients had with their
nurse provider could have made changing their behaviour, which
hadbeenpresent for several years, during the studyperioddifﬁcult.
Thirdly, it is clear that measures of adherence are not consistent,
nd clinical variables
15
e (95% CI)
Control
V4 – V0 n=481
Mean change (95% CI)
Intervention-Control
V4 – V4 n=996
Mean change (95% CI)
to 1.30) –1.22 (–2.76 to 0.33) 2.12 (–0.42 to 4.67)
to –0.10)* –0.77 (–1.92 to 0.39) 0.59 (–2.20 to 1.15)
to 5.4) 1.3 (–4.1 to 6.6) –5.4 (–12.4 to 1.6)
to 0.20) 0.18 (0.06 to 0.31)* 0.62 (–0.16 to 1.40)
to 0.05) 0.04 (0.01 to 0.07)* 0.06 (–0.04 to 0.16)
to 37.2)* 18.5 (15.5 to 21.5)* 10.1 (–2.6 to 22.9)
14.0)* 5.5 (2.7 to 8.3)* 7.0 (–2.2 to 16.1)
to 0.41)* 0.14 (0.01 to 0.27)* 0.25 (–0.10 to 0.59)
to 1.1) –1.9 (–0.5 to 3.2)* 2.6 (0.8 to 4.5)*
13.6)* 8.8 (4.9 to 12.6)* 0.1 (–0.7 to 3.4)
to 3.3) –0.6 (–1.7 to 0.5) 1.4 (–1.1 to 3.9)
to 6.2) 0.7 (–2.8 to 4.2) 1.6 (–4.0 to 7.3)
7.5)* 2.8 (– 0.1 to 5.7) 1.3 (–2.0 to 0.1)
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nd it is not clear which of the instruments currently available is
he most appropriate.16,34,35
In conclusion, our study evaluated an intervention based on
epeated information given to the HTA patient by the clinic nurse
ithin a primary care setting with negative results regarding HTA
dherence and control. Further studies are warranted to deﬁne
nd reinforce adherence, and to design more speciﬁc interven-
ions directed towards improving adherence among long termHTA
atients in the primary health care framework that are feasible and
asy to apply in every day practice.
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